The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
about
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.RIP1 expression is necessary for CD30-mediated cell death induction in anaplastic large-cell lymphoma cells.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureNovel therapies for Hodgkin Lymphoma.Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Immunotherapies for Hodgkin's lymphoma.Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.Drug development for recurrent and refractory classical Hodgkin lymphoma.Emerging drugs for Hodgkin's lymphoma.CD30: an important new target in hematologic malignancies.Molecular genetics of peripheral T-cell lymphomas.Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.
P2860
Q30248284-282B7568-B410-45CD-B21E-8D2711B6274BQ33375800-F0C2FA8A-189A-4C27-91E8-430AA5F3193CQ34643604-D8D3A22D-C49A-404D-BEC4-1482673D429AQ35038852-DAE2039D-C4C6-4BE6-91FE-A8831245F4EEQ36612532-012080C5-87CC-4D66-B6EA-C4F36BE815DCQ36771224-7174A5D9-278B-40B8-9EEB-F35004BB4F76Q37006427-B25CC824-192C-4E18-9207-45CF06242B04Q37326210-9EA14517-B6AA-4D21-9407-A22BC08866F5Q37448408-7F87C516-A500-4ACC-9365-FA9C4ADF3E1DQ37772513-B102B42C-B03B-4283-A795-B68AD122E72FQ37880873-90600F93-3B16-4086-B62D-4A7B3D40D53DQ38183757-B50134B4-53D4-4692-BD3F-A83DFAFD6865Q39567948-31D0A326-B95C-4566-9D58-9C9EE4195E33Q39778764-4063C20C-AF03-4711-B066-AA037A743FFAQ40026531-0DDC2C7D-93E1-430B-A690-CC75B77980C2Q55401659-E137F72D-9C98-4515-845D-06943E5B0D67
P2860
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The fully human anti-CD30 anti ...... bortezomib-induced apoptosis.
@en
type
label
The fully human anti-CD30 anti ...... bortezomib-induced apoptosis.
@en
prefLabel
The fully human anti-CD30 anti ...... bortezomib-induced apoptosis.
@en
P2093
P1433
P1476
The fully human anti-CD30 anti ...... bortezomib-induced apoptosis.
@en
P2093
Achim Rothe
Andreas Engert
Boris Böll
Friederike Heuck
Hinrich Hansen
Katrin Reiners
Peter Borchmann
P304
P356
10.1182/BLOOD-2005-01-0427
P407
P577
2005-05-05T00:00:00Z